Project Grant R50CA305050
Award Date 8/1/25
Completion Date 5/31/30
Dollars Obligated $230K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding of $513,542.00 to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, to conduct research on the role of p53 in regulating chaperone-mediated autophagy and its impact on tumorigenesis. The research aims to define the mechanisms by which p53, a frequently mutated gene in human cancers, suppresses tumor...
- This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
- This federal Project Grant award for $2,679,816.00, provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports four integrated research projects that aim to address key aspects of mutant p53 and its role in tumor metastasis. The funded research, led by principal investigator James Manfredi, focuses on systematic studies of mutant p53 allelic variation, mechanisms of the hot-spot mutant p53R175H in tumor metastasis, defining the roles of mutant p53...
- The National Institute of General Medical Sciences (NIGMS) awarded a $183,125 Project Grant under CFDA 93.859 - Biomedical Research and Research Training to the San Jose State University Research Foundation to study the biophysical effects of the cellular environment on the stability and aggregation of the tumor suppressor proteins p53 and PTEN. The research aims to systematically investigate how endogenous metabolites and post-translational modifications impact the conformational stability of...
- This federal Project Grant award of $590,625.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by the University of California, Davis to develop a novel therapeutic strategy targeting mutant p53 in cancer. The key objectives are to: Determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and evaluate the role of mutant p53 as a target for CDK4/6 inhibitors to suppress triple negative breast cancers (TNBCs)....
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,916.00 to the University of Massachusetts Medical School to investigate factors contributing to chemoresistance in BRCA mutant hereditary breast and ovarian cancers. The overall goal is to gain a new understanding of the mechanisms behind chemoresistance in these cancers, which frequently develop resistance to existing chemotherapies and PARP inhibitors. The research aims to...
- This $238,722 federal Project Grant awarded on August 18, 2025 by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research supports research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The research aims to define the specific mechanisms that promote mutagenic DNA repair and drive acquired drug resistance in persister cancer cells, focusing on the role of the microhomology-mediated end...
- This federal Project Grant award of $194,914 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the role of trans-acting factors and cis-element sequences in activating oncogenes in rearranged human genomes. The awardee, the University of Texas Health Science Center at Houston, will employ CRISPR/Cas9 genome engineering to introduce chromosomal translocations near oncogenes and model their expression using single-cell multi-omic...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $109,076 to The Trustees of the University of Pennsylvania to identify genes that limit chimeric antigen receptor T (CAR T) cell persistence in solid tumors. The research aims to determine the relationship between cell-extrinsic interleukin-2 (IL-2) and CAR T cell persistence in solid tumors, and hypothesizes that cell-extrinsic IL-2 can rescue persistence and enhance antitumor activity of...